Abstract
RadNet will report third‑quarter 2026 results on November 8, 2026 Post‑Mkt; consensus points to revenue of 644.63 million US dollars and adjusted EPS of 0.21, with investors watching margin resilience and execution on AI and professional services initiatives.
Market Forecast
Consensus for the third quarter centers on revenue of 644.63 million US dollars, up 30.38% year over year, EBIT of 44.18 million US dollars, up 13.44% year over year, and adjusted EPS of 0.21, down 6.01% year over year; gross profit margin and net profit margin aren’t explicitly forecast by consensus, though last quarter’s reference points were 15.20% and 1.21%, respectively.
The main business remains the service-fee engine, supported by solid imaging volumes and pricing discipline; last quarter’s service-fee revenue was 592.59 million US dollars, with total revenue growing 24.99% year over year.
Last Quarter Review
RadNet delivered revenue of 622.72 million US dollars, a gross profit margin of 15.20%, GAAP net income attributable to shareholders of 7.53 million US dollars with a net profit margin of 1.21%, and adjusted EPS of 0.29, down 6.45% year over year.
A key highlight was the sharp quarter‑on‑quarter rebound in GAAP net profit, which rose 122.50%, reflecting improved operating leverage against prior‑quarter cost pressures and execution on scheduling and modality mix.
Main business performance was anchored by service-fee revenue of 592.59 million US dollars and other arrangement revenue of 30.13 million US dollars, while total revenue advanced 24.99% year over year on strong modality throughput and continued network utilization.
Current Quarter Outlook
Core Imaging Services
Core imaging services are set to remain the principal earnings driver this quarter, supported by throughput across MRI, CT, mammography, and ultrasound. The revenue projection of 644.63 million US dollars, up 30.38% year over year, implicitly assumes sustained volumes and a broadly intact pricing environment, with EBIT expected at 44.18 million US dollars, up 13.44% year over year. Margin cadence in the core business is likely to be influenced by staffing availability, payer mix, and operational efficiency, with scheduling density and case‑mix shifts toward higher‑complexity modalities helping offset inflationary cost elements. The prior quarter’s 15.20% gross margin and 1.21% net margin provide a baseline; management’s actions to reduce frictional costs in scheduling, enhance radiologist productivity, and optimize equipment utilization are essential to preserving earnings quality. Adjusted EPS is forecast at 0.21, down 6.01% year over year, a signal that cost investments and mix dynamics may cap per‑share earnings despite top‑line strength, making labor productivity and modality yield critical to protecting profitability.
Growth Platforms and Integration
RadNet’s growth platforms—artificial intelligence solutions marketed under the DeepHealth brand and expanding professional services—are poised to contribute strategic value even if near‑term revenue is dominated by core imaging. The company announced an agreement to acquire ONRAD, a provider of teleradiology and in‑hospital professional radiology staffing services, in a cash‑and‑stock deal with an earnout, with ONRAD planned as the foundation of a third reportable operating segment, Radiology Professional Services. While the transaction is expected to close early in 2027, the strategic implications are immediate: it diversifies service lines, extends into hospital‑based professional services, and creates a platform to capture incremental demand for off‑site reads and coverage solutions that complement the outpatient network. DeepHealth’s AI workflow is strategically important in breast imaging and other modalities, accelerating reads and triage, which can translate into higher throughput and improved diagnostic performance; operationally, that can free radiologist time, elevate quality metrics, and support margin retention as case volumes scale. In this quarter, investors will look for signs that AI‑assisted workflow adoption is broadening and that commercial traction with health systems and payers is tangible, even as adjusted EPS is guided lower year over year; evidence of improved productivity or turnaround times will be read positively for medium‑term margin durability.
Key Stock Price Drivers
Stock price sensitivity this quarter revolves around three levers: revenue beat/miss against the 644.63 million US dollars consensus, margin trajectory versus the prior quarter’s 15.20% gross and 1.21% net benchmarks, and clarity on the path to monetizing growth platforms. A revenue outperformance, coupled with commentary that gross margin can hold or improve despite labor and input inflation, would be viewed constructively; conversely, a margin dip without a clear productivity narrative could weigh on sentiment, particularly given adjusted EPS is projected to decline 6.01% year over year. Investors will scrutinize staffing plans and productivity initiatives; the collaboration with WIN‑NextGen to build the talent pipeline is an incremental positive for future staffing resiliency, but near‑term effects hinge on scheduling efficiency, overtime needs, and reliance on locum tenens coverage. Any update on the ONRAD integration roadmap and AI commercialization wins—such as expanded deployments, algorithm performance metrics, or payer-facing clinical value propositions—can help frame medium‑term EBIT uplift and EPS accretion, supporting the equity story despite temporary EPS pressure. The net profit’s 122.50% quarter‑on‑quarter rebound last quarter underscores operational recovery dynamics; sustained momentum and better visibility into cost curves will likely define whether shares react favorably to the print and guidance commentary.
Analyst Opinions
Bullish opinions dominate the recent sell‑side and institutional commentary collected during the period, with no materially bearish calls identified in the coverage, resulting in a decisively positive ratio. Barclays maintained a Buy rating on RadNet, with a 79 US dollars price target, underscoring confidence in execution and the trajectory of revenue growth supported by operational improvements and strategic initiatives. Truist reiterated a Buy rating and increased its price target to 94 US dollars, citing strong performance and improved visibility into the company’s outlook following record quarterly revenue and a guidance raise earlier in the year. The prevailing bullish view is anchored in three themes: the durability of revenue expansion implied by the 30.38% year‑over‑year consensus rise, the structural benefits of AI‑enabled workflow that can support throughput and quality, and the strategic extension into professional services through the ONRAD platform, which broadens addressable opportunity and mitigates single‑segment concentration risk. Analysts note that adjusted EPS is expected to recede 6.01% year over year, but they see this as a function of elevated growth investments and integration planning rather than deterioration in demand or pricing power; if management demonstrates cost discipline, leverages AI to enhance productivity, and lays out a detailed integration framework for ONRAD, several expect EBIT to track the 13.44% year‑over‑year consensus increase and set up for continued margin normalization. Taken together, the majority opinion is that RadNet is positioned to meet or modestly exceed revenue expectations, substantiate an EBIT uptrend, and provide constructive updates on its growth platforms, which would validate the bullish stance even within the context of near‑term EPS pressure.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments